Contribution of toll-like receptor signaling pathways to breast tumorigenesis and treatment

References

• American Cancer SocietyCancer Facts and Figures 2013Atlanta, GeorgiaAmerican Cancer Society2013 Available at http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf. Accessed
   Google Scholar
• SiegelRNaishadhamDJemalACancer statistics, 2012CA Cancer J Clin2012621102922237781
   PubMed Web of Science ®Google Scholar
• AhmedAWangJHRedmondHPSilencing of TLR4 Increases Tumor Progression and Lung Metastasis in a Murine Model of Breast CancerAnn Surg Oncol Epub8142012
   Web of Science ®Google Scholar
• KimSHagemannADeMicheleAImmuno-modulatory gene polymorphisms and outcome in breast and ovarian cancerImmunol Invest2009383–432434019811442
   PubMed Web of Science ®Google Scholar
• PensaSWatsonCJPoliVStat3 and the inflammation/acute phase response in involution and breast cancerJ Mammary Gland Biol Neoplasia200914212112919424782
   PubMed Web of Science ®Google Scholar
• HojillaCVWoodGAKhokhaRInflammation and breast cancer: metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancerBreast Cancer Res200810220518394187
   PubMed Web of Science ®Google Scholar
• MedzhitovRJanewayCAJrInnate immunity: impact on the adaptive immune responseCurr Opin Immunol199791499039775
   PubMed Web of Science ®Google Scholar
• HoebeKJanssenEBeutlerBThe interface between innate and adaptive immunityNat Immunol200451097197415454919
   PubMed Web of Science ®Google Scholar
• KutikhinAGAssociation of polymorphisms in TLR genes and in genes of the Toll-like receptor signaling pathway with cancer riskHum Immunol201172111095111621872627
   PubMed Web of Science ®Google Scholar
• KutikhinAGYuzhalinAEInherited variation in pattern recognition receptors and cancer: dangerous liaisons?Cancer Manag Res20124313822427729
   PubMedGoogle Scholar
• AhmadHGubbelsREhlersEKaposi sarcoma-associated herpesvirus degrades cellular Toll-interleukin-1 receptor domain-containing adaptor-inducing beta-interferon (TRIF)J Biol Chem2011 Mar 11286107865787221212282
   PubMed Web of Science ®Google Scholar
• SayiAKohlerETollerIMTLR-2-activated B cells suppress Helicobacter-induced preneoplastic gastric immunopathology by inducing T regulatory-1 cellsJ Immunol2011 Jan 15186287889021149607
   PubMed Web of Science ®Google Scholar
• KunduSDLeeCBillipsBKThe toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cellsProstate2008 Feb 168222322918092352
   PubMed Web of Science ®Google Scholar
• PrinzCSchwendySVolandPH pylori and gastric cancer: shifting the global burdenWorld J Gastroenterol200612345458546417006981
   PubMed Web of Science ®Google Scholar
• MantovaniAMolecular pathways linking inflammation and cancerCurr Mol Med201010436937320455855
   PubMed Web of Science ®Google Scholar
• MantovaniAGarlandaCAllavenaPMolecular pathways and targets in cancer-related inflammationAnn Med201042316117020384432
   PubMed Web of Science ®Google Scholar
• KunduSDLeeCBillipsBKThe toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cellsProstate200868222322918092352
   PubMed Web of Science ®Google Scholar
• AmaranteMKWatanabeMAThe possible involvement of virus in breast cancerJ Cancer Res Clin Oncol2009135332933719009309
   PubMed Web of Science ®Google Scholar
• LawsonJSGlennWKWhitakerNJBreast cancer as an infectious diseaseWomens Health (Lond Engl)2010615820088725
   PubMedGoogle Scholar
• JoshiDBuehringGCAre viruses associated with human breast cancer? Scrutinizing the molecular evidenceBreast Cancer Res Treat2012135111522274134
   PubMed Web of Science ®Google Scholar
• LiXJiangSTappingRIToll-like receptor signaling in cell proliferation and survivalCytokine20104911919775907
   PubMed Web of Science ®Google Scholar
• Rakoff-NahoumSMedzhitovRToll-like receptors and cancerNat Rev Cancer200991576319052556
   PubMed Web of Science ®Google Scholar
• JingZZHeXBFangYXJiaHJZhouTModulation of the host toll-like receptor signaling pathways by virus infectionBing Du Xue Bao2012284453461 Chinese22978173
   PubMedGoogle Scholar
• TakedaKAkiraSToll-like receptorsCurr Protoc Immunol2007 Chapter 14:Unit 14.12
   PubMedGoogle Scholar
• PisetskyDSThe origin and properties of extracellular DNA: from PAMP to DAMPClin Immunol20121441324022659033
   PubMed Web of Science ®Google Scholar
• AkiraSTakedaKToll-like receptor signallingNat Rev Immunol20044749951115229469
   PubMed Web of Science ®Google Scholar
• AkiraSTakedaKKaishoTToll-like receptors: critical proteins linking innate and acquired immunityNat Immunol20012867568011477402
   PubMed Web of Science ®Google Scholar
• BlasiusALBeutlerBIntracellular toll-like receptorsImmunity201032330531520346772
   PubMed Web of Science ®Google Scholar
• LeeCAvalosAPloeghHAccessory molecules for Toll-like receptors and their functionNat Rev Immunol20121216817922301850
   PubMed Web of Science ®Google Scholar
• MotshwenePGMoncrieffeMCGrossmannJGAn oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4J Biol Chem200928437254042541119592493
   PubMed Web of Science ®Google Scholar
• LinSCLoYCWuHHelical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signallingNature2010465730088589020485341
   PubMed Web of Science ®Google Scholar
• GayNJGangloffMO’NeillLAWhat the Myddosome structure tells us about the initiation of innate immunityTrends Immunol201132310410921269878
   PubMed Web of Science ®Google Scholar
• BartonGMMedzhitovRToll-like receptor signaling pathwaysScience200330056251524152512791976
   PubMed Web of Science ®Google Scholar
• SnoussiKMahfoudhWBouaouinaNAhmedSBHelalANChouchaneLGenetic variation in IL-8 associated with increased risk and poor prognosis of breast carcinomaHum Immunol2006671–2132116698420
   PubMed Web of Science ®Google Scholar
• KarinMNuclear factor-kappaB in cancer development and progressionNature2006441709243143616724054
   PubMed Web of Science ®Google Scholar
• O’NeillLABowieAGThe family of five: TIR-domain-containing adaptors in Toll-like receptor signallingNat Rev Immunol20077535336417457343
   PubMed Web of Science ®Google Scholar
• HsuLCParkJMZhangKThe protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4Nature2004428698034134515029200
   PubMed Web of Science ®Google Scholar
• AliprantisAOYangRBWeissDSGodowskiPZychlinskyAThe apoptotic signaling pathway activated by Toll-like receptor-2EMBO J200019133325332610880445
   PubMed Web of Science ®Google Scholar
• XieWWangYHuangYYangHWangJHuZToll-like receptor 2 mediates invasion via activating NF-kappaB in MDA-MB-231 breast cancer cellsBiochem Biophys Res Commun200937941027103219141294
   PubMed Web of Science ®Google Scholar
• ParkBKZhangHZengQNF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSFNat Med2007131626917159986
   PubMed Web of Science ®Google Scholar
• KarinMCaoYGretenFRLiZWNF-kappaB in cancer: from innocent bystander to major culpritNat Rev Cancer20022430131012001991
   PubMed Web of Science ®Google Scholar
• SalaunBCosteIRissoanMCLebecqueSJRennoTTLR3 can directly trigger apoptosis in human cancer cellsJ Immunol200617684894490116585585
   PubMed Web of Science ®Google Scholar
• SalaunBZitvogelLAsselin-PaturelCTLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancerCancer Res20117151607161421343393
   PubMed Web of Science ®Google Scholar
• YangHZhouHFengPReduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretionJ Exp Clin Cancer Res2010299220618976
   PubMed Web of Science ®Google Scholar
• González-ReyesSMarínLGonzálezLStudy of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasisBMC Cancer201010166521129170
   PubMed Web of Science ®Google Scholar
• BergerRFieglHGoebelGToll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumorsCancer Sci201010141059106620156214
   PubMed Web of Science ®Google Scholar
• MerrellMAIlvesaroJMLehtonenNToll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activityMol Cancer Res20064743744716849519
   PubMed Web of Science ®Google Scholar
• JózsefLKhreissTFilepJGCpG motifs in bacterial DNA delay apoptosis of neutrophil granulocytesFASEB J200418141776177815345690
   PubMed Web of Science ®Google Scholar
• El AndaloussiASonabendAMHanYLesniakMSStimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumorsGlia200654652653516906541
   PubMed Web of Science ®Google Scholar
• FischerSFRehmMBauerAToll-like receptor 9 signaling can sensitize fibroblasts for apoptosisImmunol Lett200597111512215626483
   PubMed Web of Science ®Google Scholar
• EtokebeGEKnezevićJPetricevićBPavelićJVrbanecDDembićZSingle-nucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4, and -9 in case-control study with breast cancerGenet Test Mol Biomarkers200913672973419810822
   PubMed Web of Science ®Google Scholar
• TheodoropoulosGESaridakisVKarantanosTToll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer developmentBreast201221453453822560646
   PubMed Web of Science ®Google Scholar
• FerwerdaBMcCallMBVerheijenKFunctional consequences of toll-like receptor 4 polymorphismsMol Med2008145–634635218231573
   PubMed Web of Science ®Google Scholar
• SchröderNWSchumannRRSingle nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious diseaseLancet Infect Dis20055315616415766650
   PubMed Web of Science ®Google Scholar
• AgneseDMCalvanoJEHahmSJHuman toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infectionsJ Infect Dis2002186101522152512404174
   PubMed Web of Science ®Google Scholar
• ChildNJYangIAPulletzMCPolymorphisms in Toll-like receptor 4 and the systemic inflammatory response syndromeBiochem Soc Trans200331Pt 365265312773175
   PubMed Web of Science ®Google Scholar
• FaberJMeyerCUGemmerCHuman toll-like receptor 4 mutations are associated with susceptibility to invasive meningococcal disease in infancyPediatr Infect Dis J12006251808116395111
   PubMed Web of Science ®Google Scholar
• FraudendorfHGelbrichWReimerWHeringBEffect of experimentally induced changes in blood flow on the heat and electrical conductivity of the skinActa Biol Med Ger1975345923931 German1199613
   PubMedGoogle Scholar
• SherrySTWardWHKholodovMdbSNP: the NCBI database of genetic variationNucleic Acids Res200129130831111125122
   PubMed Web of Science ®Google Scholar
• KimbroKSOpreaGMBurnsBGInnate immunity-related sequence variants as predictors of breast cancer risk among women of African descentJ Clin Oncol201028Suppl15s Abstract 1581
   Google Scholar
• Barnholtz-SloanJSShettyPBGuanXFGFR2 and other loci identified in genome-wide association studies are associated with breast cancer in African-American and younger womenCarcinogenesis20103181417142320554749
   PubMed Web of Science ®Google Scholar
• ChanMJiSLiawCAssociation of common genetic variants with breast cancer risk and clinicopathological characteristics in a Chinese populationBreast Cancer Res Treat2012136111222915072
   PubMed Web of Science ®Google Scholar
• LeeJYParkAKLeeKMCandidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean womenCarcinogenesis20093091528153119372141
   PubMed Web of Science ®Google Scholar
• BiXHameedMMiraniNPimentaEMAnariJBarnesBJLoss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasisBreast Cancer Res2011136R11122053985
   PubMed Web of Science ®Google Scholar
• GoutagnyNEstornesYHasanULebecqueSCauxCTargeting pattern recognition receptors in cancer immunotherapyTarget Oncol201271295422399234
   PubMed Web of Science ®Google Scholar
• LacourJLacourFDucotBPolyadenylic-polyuridylic acid as adjuvant in the treatment of operable breast cancer: recent resultsEur J Surg Oncol19881443113163044833
   PubMed Web of Science ®Google Scholar
• LaplancheAAlzieuLDelozierTPolyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: a 14 year follow-up analysis of a randomized trial of the Fédération Nationale des Centres de Lutte contre le Cancer (FNCLCC)Breast Cancer Res Treat200064218919111194454
   PubMed Web of Science ®Google Scholar
• PaoneAGalliRGabelliniCToll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 alphaNeoplasia201012753954920651983
   PubMed Web of Science ®Google Scholar
• ZimmerSSteinmetzMAsdonkTActivation of endothelial toll-like receptor 3 impairs endothelial functionCirc Res2011108111358136621493895
   PubMed Web of Science ®Google Scholar
• BergéMBonninPSulpiceESmall interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinomaAm J Pathol201017763192320120971743
   PubMed Web of Science ®Google Scholar
• ApetohLGhiringhelliFTesniereAToll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNat Med20071391050105917704786
   PubMed Web of Science ®Google Scholar
• SzkanderaJAbsengerGDandachiNAnalysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancerMol Genet Genomics2012287975576422903472
   PubMed Web of Science ®Google Scholar
• MaruyamaKSelmaniZIshiiHYamaguchiKInnate immunity and cancer therapyInt Immunopharmacol201111335035720955832
   PubMed Web of Science ®Google Scholar
• DieboldSSKaishoTHemmiHAkiraSReis e SousaCInnate antiviral responses by means of TLR7-mediated recognition of single-stranded RNAScience200430356631529153114976261
   PubMed Web of Science ®Google Scholar
• RechtsteinerGWargerTOsterlohPSchildHRadsakMPCutting edge: priming of CTL by transcutaneous peptide immunization with imiquimodJ Immunol200517452476248015728450
   PubMed Web of Science ®Google Scholar
• PrinsRMCraftNBruhnKWThe TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunityJ Immunol2006176115716416365406
   PubMed Web of Science ®Google Scholar
• StaryGBangertCTauberMStrohalRKoppTStinglGTumoricidal activity of TLR7/8-activated inflammatory dendritic cellsJ Exp Med200720461441145117535975
   PubMed Web of Science ®Google Scholar
• PfizerPF-3512676 (CpG 7909) injection for patients who completed an oncology study using PF-3512676 (CpG 7909)ClinicalTrials.gov [website on the Internet]Bethseda, MDUS National Library of Medicine2008 [updated March 11, 2009]. Available from: http://clinicaltrials.gov/show/NCT00043368. NLM identifier: NCT00043368Accessed February 21, 2013
   Google Scholar
• PfizerCPG 7909 plus Herceptin® in patients with metastatic breast cancerClinicalTrials.gov [website on the Internet]Bethseda, MDUS National Library of Medicine2002 [updated March 11, 2009]. Available from: http://clinicaltrials.gov/show/NCT00043394. NLM identifier: NCT00043394Accessed February 21, 2013
   Google Scholar
• PfizerSafety and efficacy study of the combination of CpG 7909 and Herceptin in patients with metastatic breast cancerClinicalTrials.gov [website on the Internet]Bethseda, MDUS National Library of Medicine2002 [updated May 26, 2011]. Available from: http://clinicaltrials.gov/show/NCT00031278. NLM identifier: NCT00031278Accessed February 21, 2013
   Google Scholar
• Ohio State University Comprehensive Cancer CenterAgatolimod and trastuzumab in treating patients with locally advanced or metastatic breast cancerClinicalTrials.gov [website on the Internet]Bethseda, MDUS National Library of Medicine2009 [updated November 9, 2011]. Available from: http://clinicaltrials.gov/show/NCT00824733. NLM identifier: NCT00824733Accessed February 21, 2013
   Google Scholar
• VabulasRMBraedelSHilfNThe endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathwayJ Biol Chem200227723208472085311912201
   PubMed Web of Science ®Google Scholar
• TangDKangRChehCWHMGB1 release and redox regulates autophagy and apoptosis in cancer cellsOncogene201029385299531020622903
   PubMed Web of Science ®Google Scholar
• LotzeMTDeMarcoRADealing with death: HMGB1 as a novel target for cancer therapyCurr Opin Investig Drugs2003414051409
   PubMedGoogle Scholar
• LotzeMTTraceyKJHigh-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenalNat Rev Immunol2005533134215803152
   PubMed Web of Science ®Google Scholar
• XieWHuangYGuoAWuWBacteria peptidoglycan promoted breast cancer cell invasiveness and adhesiveness by targeting toll-like receptor 2 in the cancer cellsPLoS One20105e1085020520770
   PubMed Web of Science ®Google Scholar
• HiratsukaSWatanabeASakuraiYThe S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phaseNat Cell Biol200810111349135518820689
   PubMed Web of Science ®Google Scholar
• ZhangGSunXLvHYangXKangXSerum amyloid A: A new potential serum marker correlated with the stage of breast cancerOncol Lett2012394094422741023
   PubMed Web of Science ®Google Scholar
• SfondriniLRossiniABesussoDAntitumor activity of the TLR-5 ligand flagellin in mouse models of cancerJ Immunol2006176116624663016709820
   PubMed Web of Science ®Google Scholar
• CaiZSanchezAShiZZhangTLiuMZhangDActivation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growthCancer Res2011 Apr 17172466247521427357
   PubMed Web of Science ®Google Scholar